Geltex Pharmaceuticals
Founded Year
1992Stage
Acquired | AcquiredValuation
$0000About Geltex Pharmaceuticals
Geltex Pharmaceuticals develops polymer-based pharmaceuticals. It uses polymer technology for drugs that stay in the gastrointestinal tract and remove toxins. It was founded in 1992 and is based in Waltham, Massachusetts. In December 2000, Geltex Pharmaceuticals was acquired by Genzyme.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Geltex Pharmaceuticals Frequently Asked Questions (FAQ)
When was Geltex Pharmaceuticals founded?
Geltex Pharmaceuticals was founded in 1992.
Where is Geltex Pharmaceuticals's headquarters?
Geltex Pharmaceuticals's headquarters is located at 153 Second Avenue, Waltham.
What is Geltex Pharmaceuticals's latest funding round?
Geltex Pharmaceuticals's latest funding round is Acquired.
Who are the investors of Geltex Pharmaceuticals?
Investors of Geltex Pharmaceuticals include Genzyme, Norwest Venture Partners, Domain Associates and Abingworth.
Who are Geltex Pharmaceuticals's competitors?
Competitors of Geltex Pharmaceuticals include Albireo Pharma, Biocytogen, PPD, Kythera Biopharmaceuticals, Bioceros and 13 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Geltex Pharmaceuticals to Competitors
Provonix is a contract research organization focused on providing individualized clinical trial solutions to meet the needs of pharmaceutical, biotechnology, and medical device companies.
Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.
The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies
is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
